ZIPPER Aortic Arch Stent-Graft for Aortic Arch Dissection
ZIPPER™ Stent-Graft Trial for Aortic Arch Dissection
Treatment Study
Summary
Study start date: September 30, 2025
Actual date on which the first participant was enrolled.This study aims to evaluate the safety and effectiveness of a medical device called the ZIPPER™ Aortic Arch Stent-Graft System. It is designed to treat a condition known as aortic arch dissection, which is a serious issue involving a tear in the inner layer of the aorta, the large blood vessel branching off the heart. The study will also look at how well the device works in patients who have had a tear remaining after surgery on the upper part of the aorta. By understanding how well this stent-graft works, the study could help improve treatment options for people suffering from this condition, potentially making procedures safer and more effective. The study will include 127 participants who will receive the ZIPPER aortic arch stent-graft system. Being an interventional study, it focuses on observing the effects of this specific treatment. Although specific methods of measuring results are not detailed, studies like this typically keep a close watch on both the benefits, such as improved blood flow, and any risks, like complications or side effects, associated with the device. The findings could lead to better management of aortic arch dissections, benefiting patients by reducing the risks associated with current treatment options.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.127 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 80 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: * Age: 18-80 years of age. Diagnosis and Anatomical Suitability: Subacute or chronic aortic arch dissection requiring intervention, where the proximal end of the stent graft requires anchoring in Zone 0, and meets the following vascular anatomical criteria: Ascending aorta (may include graft segments) ≥ 40 mm in length (measured from the sinotubular junction to the proximal edge of the IA along the centerline). Proximal landing zone diameter ≥ 24 mm and ≤ 47 mm. Proximal landing zone length ≥ 20 mm. Diameters of the IA, LCCA, and LSA ≤ 24 mm and ≥ 6 mm, with lengths ≥ 20 mm. Suitable arterial access for endovascular intervention. Informed Consent: Capable of understanding the study purpose, voluntarily agreeing to participate, and providing written informed consent (by the subject or their legal representative). Willing to comply with follow-up requirements per the protocol. Surgical Risk Assessment: Deemed high surgical risk (evaluated by at least two independent vascular or cardiac surgeons) or confirmed to have significant contraindications to open surgery. Exclusion Criteria: * Prior aortic intervention: History of open or endovascular repair of the descending or abdominal aorta. Concurrent AAA requiring intervention: Coexisting abdominal aortic aneurysm requiring surgical intervention within 30 days. Specific aortic pathologies: infectious aortitis, Takayasu arteritis, Marfan syndrome, or other connective tissue disorders. Active systemic infection: Ongoing systemic infection or high risk of systemic infection. Severe arch vessel disease: Severe stenosis, calcification, thrombosis, or tortuosity of the IA, LCCA, or LSA. Acute ischemia: Bowel necrosis or lower limb ischemic necrosis. Pre-existing paraplegia. Post-cardiac transplant status. Recent cardiovascular events: Myocardial infarction or stroke within the past 3 months. Advanced heart failure: NYHA Class IV or left ventricular ejection fraction (LVEF) \<30%. Active gastrointestinal bleeding: Active peptic ulcer or upper gastrointestinal bleeding within the past 3 months. Hematologic abnormalities: Leukopenia (WBC \< 3×10⁹/L), Anemia (Hb \< 90 g/L), Coagulopathy, Thrombocytopenia (platelets \< 50×10⁹/L). Renal insufficiency: Serum creatinine \> 221 μmol/L (2.5 mg/dL) or end-stage renal disease requiring dialysis (investigator discretion). Severe hepatic dysfunction: ALT/AST \> 5× upper limit of normal (ULN), Serum total bilirubin (STB) \> 2× ULN. High-risk intracranial lesions (any of the following): 1. Unruptured aneurysm ≥7 mm (anterior circulation) or ≥5 mm (posterior circulation) 2. Prior rupture or high-risk morphology (daughter sac, aspect ratio \>1.6) 3. Intracranial arterial stenosis ≥50% with poor collateral flow. Contrast allergy. Pregnancy or lactation. Anesthesia/surgery contraindications: Severe comorbidities precluding tolerance to anesthesia or surgery. Life expectancy \< 12 months. Current participation in other drug or device clinical trials. Other exclusions: Any conditions deemed unsuitable for participation by the investigator.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives